• Policy
• Phase 3 of Fitusiran, an all-around tx for hemophilia
• by Lee, Hye-Kyung Nov 22, 2022 06:04am

• Policy
• Gov't declines preferential pricing for innovative drugs
• by Lee, Jeong-Hwan Nov 21, 2022 05:56am

• Company
• Evrysdi can be prescribed with non-reimbursement
• by Eo, Yun-Ho Nov 21, 2022 05:56am

• Policy
• Label for rosuvastatin to change following ticagrelor
• by Lee, Hye-Kyung Nov 21, 2022 05:56am

• Company
• Dong-AST ended the clinical trial of Stelara biosimilar
• by Chon, Seung-Hyun Nov 21, 2022 05:56am

• Policy
• Public policy fee for severely ill children is implemented
• by Kim, Jung-Ju Nov 21, 2022 05:56am

• InterView
• “Korea is fully capable of developing new microbiome drugs"
• by Nho, Byung Chul Nov 18, 2022 06:04am

• Company
• KPBMA visits Boston...expands exchanges with MIT, etc.
• by Chon, Seung-Hyun Nov 18, 2022 06:04am

• Policy
• The budget for Paxlovid's SE relief will be prepared
• by Lee, Jeong-Hwan Nov 18, 2022 06:04am

• Policy
• Quick diagnosis is essential for Hepatitis C
• by Nov 18, 2022 06:03am